**Supplementary information**

# Methods

***Literature research and data extraction***

We conducted a systematic search from three peer-reviewed databases (PubMed, Web of Science and Embase) and an open science platform (Europe PMC), for studies published in English with predefined search terms **(Table S1)**.We included studies that are original analyses of COVID-19 vaccine efficacy with a randomized clinical trial design against wild type and variants, or are original analyses of COVID-19 vaccine effectiveness. Studies that were not in humans were excluded. We also excluded abstracts of congress meetings or conference proceedings, study protocols, media news, commentaries, and reviews. Detailed eligibility criteria conforming to the Population/Participants, Intervention, Comparator, Outcome, Setting/Study design (PICOS) format was summarized in **Table S2**. We screened all eligible studies to extract the following data: vaccine name, developer, study design, study location, study period, population size, age of participants, locally-circulating virus strains, overall and age-specific efficacy (full list of variables in **Tables S3 and S4)**. We previously reported a meta-analysis of *in vitro* neutralization titers of individuals who have been vaccinated with prototype-strain-based vaccines against both SARS-CoV-2 prototype strains and variants, and the data were continuously updated 1 We summarized geometric mean titers (GMTs) of neutralizing antibodies in vaccine recipients and the average reduction fold of GMTs in variants compared to the parental virus strains **(Table S5)**. The inclusion and exclusion of studies, screening and scrutinization of included studies, data extraction and verification were performed by two independent researchers, and a third researcher was consulted when disagreement arose.

**Data analysis**

For the collected efficacy data, only the efficacy after complete vaccination according to each vaccine’s immunization schedule (e.g., 7 days after two doses of BNT162b2/Pfizer, 14 days after two doses of mRNA-1273/Moderna) were used in analyses. For *in vitro* neutralizing antibody data, we prioritized using results from live virus neutralization assays, followed by those from pseudovirus neutralization assays. We also matched the doses and sampling time of subjects for which neutralizing antibody data were obtained and those in which efficacy data were obtained (e.g., BNT162b2/Pfizer vaccinees whose blood was taken within 7 days after the second dose are removed). For studies which aggregated sampling time data (e.g., using median and interquartile range to represent the sampling time for a group of people), we assumed all the people were sampled at the median/mean sampling time. For the estimation of age-specific efficacy, as age group categories were not exactly matched between efficacy data and neutralization data for mRNA-1273 vaccine, we assumed that the neutralization antibody levels for those older than 55 years old were similar to those older than 65 years.

**Statistical methods**

***Statistical model***

We followed the basic assumption that neutralizing antibodies is the best studied marker, and likely a major mechanism, of immune protection,2 though antiviral T and B cell memory likely contribute some degree of protection.3,4 Following the work by *Khoury et al*, *2* we predicted vaccine protection against variants with the following relationship between neutralizing antibody levels and vaccine efficacy **(equation 1)**, as well as an integral logistic-normal to calculate the probability of being protected **(equation 2)**.

*,* (1)

(2)

Alogistic model was assumed to model the relationship for equation (1), where *EI* is the vaccine efficacy given the log-transformed neutralizing antibody titer *n*. *n50* is the neutralization titer at which an individual will have a 50% protective efficacy. The parameter *k* controls the steepness of the logistic function.2 For equation (2), assuming that neutralizing antibodies follow a normal distribution with mean *μs* and standard deviation *σs* (here the pooled standard deviation estimated from a combined dataset of neutralization titers from all studies was used)2, the *f* indicates the probability density function of neutralization titer. represents the proportion of vaccinated population for a study *s* that will be protected.2

*Estimating efficacy of variants against COVID-19 symptomatic and severe case*

Using previous **equations (1)**, we firstly modelled the relationship between efficacy against the prototype strain and neutralizing titers as *Khoury et al*., described.2 Then, distributions of fold changes in neutralizing antibodies for different variants were added into the model to predict changes in efficacy for each vaccine. For the parameters used in this model, the slope *k* for COVID-19 symptomatic and severe cases, and pooled standard deviation *σs* were the same as reported by *Khoury et al*.

*Estimating efficacy of variants against SARS-CoV-2 infection*

For the estimation of efficacy against infection, firstly, we used the binomial probability function and likelihood **(equation 3)** to estimate the parameter *k and n50* by fitting the efficacy data of infections and symptomatic cases from phase 3 clinical trials (due to limited number of studies for infection alone) according to methods reported by *Khoury et al*.2

*,* (3)

where *bs* is the probability of an unvaccinated individual (control) being infected

in study *s*, *bs(1−P(n50, k, μs, σs))* is the probability of infection in

the vaccinated individuals and *Bi(N, K, p)* is the binomial probability

mass function of the probability of *K* events from a sample size of *N*, for which

each event has a probability *P*. Second, similar to estimation of efficacy against symptomatic and severe, the fold-change of neutralizing antibody level of variants were added to predict efficacy against SARS-CoV-2 infection according to both **equation (1)** and **equation (2)**.

*Estimating uncertainty intervals*

We used the 95% confidence intervals of fold-change of neutralizing titers, combined with the 95% confidence interval of efficacy against prototype strains, and selected the highest and the lowest estimates to be the upper and lower limits of our uncertainty intervals. All statistical analyses were done using R (version 4.0.1).

# Supplementary Tables

## Table S1. Search strategy for studies that reported COVID-19 vaccine efficacy and effectiveness

|  |  |  |  |
| --- | --- | --- | --- |
| Database | Step | Search strategy | Number of articles\* |
| Pubmed | #1 | COVID-19[All Fields] | 143,932  |
| #2 | vaccin\*[Title/Abstract] or immunization[Title/Abstract] | 387,536  |
| #3 | #1 AND #2 | 11,504  |
| #4 | COVID-19 Vaccines[MeSH Terms] | 2,954  |
| #5 | #3 OR #4 | 12,046  |
| #6 | BNT162b2[All Fields] OR Pfizer-BioNTech[All Fields] OR Pfizer/BioNTech[All Fields] OR Comirnaty[All Fields] | 480  |
| #7 | mRNA-1273[All Fields] OR Moderna COVID-19 vaccine[All Fields] | 179  |
| #8 | ChAdOx1 nCoV-19[All Fields] OR AZD1222[All Fields] OR ChAdOx1-S[All Fields] OR Oxford-AstraZeneca[All Fields] OR Covishield[All Fields] | 186  |
| #9 | Gam-COVID-Vac[All Fields] OR Sputnik V[All Fields] | 25  |
| #10 | Ad5 nCoV[All Fields] OR Cansino[All Fields] | 130  |
| #11 | BBIBP-CorV[All Fields] OR WBIP[All Fields] OR Sinopharm[All Fields] | 145  |
| #12 | CoronaVac[All Fields] OR SinoVac[All Fields] | 105  |
| #13 | BBV152[All Fields] OR Covaxin[All Fields] OR Bharat Biotech[All Fields] | 69  |
| #14 | Ad26.COV2.S[All Fields] OR Janssen COVID-19 Vaccine[All Fields] | 49  |
| #15 | ZF2001[All Fields] OR Anhui Zhifei Longcom[All Fields] | 9  |
| #16 | EpiVacCorona[All Fields] | 1  |
| #17 | KCONVAC[All Fields] | 1  |
| #18 | #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 | 1,149  |
| #19 | #5 OR #18 | 12,450  |
| #20 | Immunogenicity, Vaccine[MeSH Terms] | 2,065  |
| #21 | Immunity[MeSH Terms] | 395,451  |
| #22 | immunogenic\*[Title/Abstract] | 65,142  |
| #23 | effic\*[Title/Abstract] | 1,924,784  |
| #24 | effect\*[Title/Abstract] | 7,388,003  |
| #25 | immune\*[Title/Abstract] | 692,578  |
| #26 | respons\*[Title/Abstract] | 3,396,441  |
| #27 | protect\*[Title/Abstract] | 864,520  |
| #28 | #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 | 10,982,066  |
| #29 | #19 AND #28 | 7,825  |
| Web of Science | #1 | TS = COVID-19 | 172,501  |
| #2 | TS = vaccin\* | 658,077  |
| #3 | #1 AND #2 | 13,138  |
| #4 | TS = (BNT162b2 OR Pfizer-BioNTech OR Pfizer/BioNTech OR Comirnaty) | 456  |
| #5 | TS = (mRNA-1273 OR Moderna COVID-19 vaccine) | 287  |
| #6 | TS = (ChAdOx1 nCoV-19 OR AZD1222 OR ChAdOx1-S OR Oxford-AstraZeneca OR Covishield) | 172  |
| #7 | TS = (Gam-COVID-Vac OR Sputnik V) | 71  |
| #8 | TS = (Ad5 nCoV OR Cansino) | 37  |
| #9 | TS = (BBIBP-CorV OR WBIP OR Sinopharm) | 35  |
| #10 | TS = (CoronaVac OR SinoVac) | 58  |
| #11 | TS = (BBV152 OR Covaxin OR Bharat Biotech) | 44  |
| #12 | TS = (Ad26.COV2.S OR Janssen COVID-19 Vaccine) | 62  |
| #13 | TS = (ZF2001 OR Anhui Zhifei Longcom) | 6  |
| #14 | TS = (EpiVacCorona) | 3  |
| #15 | TS = (KCONVAC) | 1  |
| #16 | #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 | 945  |
| #17 | #3 OR #16 | 13,378  |
| #18 | TS = immunogenic\* | 122,444  |
| #19 | TS = effic\* | 12,789,042  |
| #20 | TS = effect\* | 31,459,770  |
| #21 | TS = immune\* | 3,671,086  |
| #22 | TS = repons\* | 11,044  |
| #23 | TS = protect\* | 5,459,212  |
| #24 | #18 OR #19 OR #20 OR #21 OR #22 OR #23 | 45,061,106  |
| #25 | #17 AND #24 | 8,553  |
| Embase | #1 | coronavirus disease 2019'/de  | 123,978  |
| #2 | COVID-19 | 127,066  |
| #3 | #1 OR #2 | 143,296  |
| #4 | vaccin\* | 561,441  |
| #5 | #3 AND #4 | 12,442  |
| #6 | bnt162b2 OR 'Pfizer BioNTech' OR Comirnaty | 395  |
| #7 | mRNA-1273 OR 'Moderna COVID-19 vaccine' | 267  |
| #8 | ChAdOx1 nCoV-19' OR AZD1222 OR ChAdOx1-S OR 'Oxford AstraZeneca' OR Covishield | 275  |
| #9 | Gam-COVID-Vac OR 'Sputnik V' | 85  |
| #10 | Ad5 nCoV' OR Cansino | 397  |
| #11 | BBIBP-CorV OR WBIP OR Sinopharm | 833  |
| #12 | CoronaVac OR SinoVac | 311  |
| #13 | BBV152 OR Covaxin OR 'Bharat Biotech' | 202  |
| #14 | Ad26.COV2.S OR 'Janssen COVID-19 Vaccine' | 73  |
| #15 | ZF2001 OR 'Anhui Zhifei Longcom' | 26  |
| #16 | EpiVacCorona | 10  |
| #17 | KCONVAC | 1  |
| #18 | #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 | 2,186  |
| #19 | #5 OR #18 | 13,857  |
| #20 | immunogenic\* | 107,428  |
| #21 | effic\* | 3,077,373  |
| #22 | effect\* | 10,582,126  |
| #23 | immune\* | 1,251,886  |
| #24 | repons\* | 8,581  |
| #25 | protect\* | 1,363,644  |
| #26 | #20 OR #21 OR #22 OR #23 OR #24 OR #25 | 13,288,803  |
| #27 | #19 AND #26 | 8,581  |
| Europe PMC | #1 | COVID-19 AND vaccin\* | 54,038  |
| #2 | immunogenic\* OR effect\* OR effic\* OR immune\* OR protect\* OR protect\* | 13,826,389  |
| #3 | Type: Preprints | 307,380  |
| #4 | #1 AND #2 AND #3 | 11,583  |

## Table S2. Inclusion and exclusion criteria of searched studies

|  |  |
| --- | --- |
| Population or participants | Population without immunosuppressive conditions, including females and/or males of any age group, with or without prior SARS-CoV-2 infection, exclude HIV-positive, cancer, Organ Transplant Recipients, Pregnant Women and so on. |
| Intervention or exposure | COVID-19 candidate vaccine (BNT162b2, mRNA-1273, BBIBP-CorV, WBIP, CoronaVac, BBV152, ChAdOx1 nCoV-19, Gam-COVID-Vac, Ad5 nCoV and so on) |
| Comparison groups | 1) Placebo, and/or other vaccine adminstrate2) No COVID-19 vaccination. |
| Primary outcomes | Efficacy and Effectiveness against SARS-CoV-2 (wild type and variants) associated clinical outcomes (including, but not limited to, symptomatic case, medical attendance, death) |
| Setting | Any setting within any geographical location. |
| Study designs | Any study including participants who received COVID-19 vaccine through a clinical trial, and where data were presented by number of doses received. This could include the original clinical trial in which vaccine was administered or subsequent observational studies, e.g. prospective cohort, cross-sectional studies or case-control studies. |
| Language | Restricted to English-language publications. |
| Exclusion criteria | Studies not meeting inclusion criteria were excluded. Additionally:1. Studies that were not in humans.
2. review, modelling study
 |

## Table S3. Summary of vaccine efficacy from included studies

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **Developer** | **Study location** | **Population size** | **Age range** | **Design/Measure of effect** | **Circulation of VOCs** | **Period** | **Against infection** | **Against symptomatic case** | **Against hospitalization** | **Against severe outcome** |
| **mRNA** |
| BNT162b2 | BioNTech/Pfizer | United States5 | 2,260  | 12-15 years | RCT/Efficacy | Prototype | 7 days after dose 2 | - | 100.0 (75.3-100) | - | - |
| United States, Argentina, Brazil, South Africa6 | 43,355  | ≥16 years | After dose 1\* | - | 82.0 (75.6-86.9) | - | 88.9 (20.1-99.7) |
| 37,706  | ≥16 years | 7 days after dose 2 | - | 95.0 (90.3-97.6) | - | 75.0 (-152.6, 99.5) |
| 21,785  | 16-55 years | - | 95.6 (89.4-98.6) | - | - |
| 15,921  | > 55 years | - | 94.7 (66.7-99.9) | - | - |
|  |  | - |  | - | - |
|  |  | - |  | - | - |
|  |  | United States, Argentina, Brazil, South Africa7 |  | ≥ 12 years | RCT/Efficacy | Mixed | 7 days after dose 2 | - | 91.2 (88.9, 93.0) | - | 95.7 (73.9-99.9) |
|  |  |  |  | 16-17 years | - | 100.0 (58.0-100.0) | - | - |
|  |  |  |  | 16-55 years | - | 91.2 (88.3-93.5) | - | - |
|  |  |  |  | > 55 years | - | 90.9 (86.3-94.2) | - | - |
|  |  |  |  | ≥ 65 years | - | 94.5 (88.3-97.8) | - | - |
|  |  |  |  | ≥ 75 years | - | 96.2 (76.9-99.9) | - | - |
| mRNA-1273 | Moderna | United States8 | 3,700  | 12-17 years | RCT/Efficacy | Prototype | 14 days after dose 2 | - | 100.0 | - | - |
| 28,207  | ≥18 years | 89.6 (85.2-92.6)\* | 94.1 (89.3-96.8) | - | 100.0 (NE-100.0) |
| 21,072  | 18-65 years | - | 95.6 (90.6-97.9) | - | - |
| 7,135  | ≥65 years | - | 86.4 (61.4-95.2) | - | - |
| **Inactivated** |
| CoronaVac | SinoVac | Brazil9 | 12,688  | >18 years | RCT/Efficacy | Prototype, P.1 | 14 days after dose 2 | - | 50.7 (35.9-62.0) | 100 (56-100) | 100.0 (16.9-100.0) |
| 9,404  | 18-59 years | - | 50.7 (35.8-62.1) | - | - |
| 419 | ≥ 60 years | - | 51.1 (-166.9-91.0) | - |  |
| Brazil10 |  | >18 years | B.1.1.28 | - | 73 (46-86) | - | - |
|  | >18 years | P.2 | - | 69 (55-78) | - | - |
|  | >18 years | B.1.1.33 | - | 88.2 (5-99) | - | - |
|  | >18 years | P.1 | - | 64 (-2-87) | - | - |
| Turkey11 | 10,218 | ≥18 years | Prototype | - | 83.5 (65.4-92.1) | - | 100 (20.4-100) |
| Indonesia12 | 1,602  | ≥18 years | - | 65 (20-85) | - | - |
| BBIBP-Corv | Sinopharm | Multi-country13 | 12,726  | ≥18 years | RCT/Efficacy | Prototype | 14 days after dose 2 | 73.5 (60.6-82.2) | 78.1 (64.8-86.3) | - | 100  |
| 12,525  | 18-59 years |  | 78.1 (64.9-86.4) | - | - |
| WBIP | Sinopharm | Multi-country13 | 12,734  | ≥18 years | RCT/Efficacy | Prototype | 14 days after dose 2 | 64.0 (48.8-74.7) | 72.8 (58.1-82.4) | - | 100 (NE) |
| 12,530  | 18-59 years | - | 72.8 (58.0-82.4) | - | - |
| BBV152 | Bharat Biotech | India14 | 16,973  | ≥18 years | RCT/Efficacy | Mixed | 14 days after dose 2 | 68.8 (46.7-82.5) | 77.8 (65.2-86.4) | - | 93.4 (57.1-99.8) |
| 15,115  | 18-59 years | Mixed | - | 79.4 (66.0-88.2) | - | - |
| 1,858  | ≥60 years | Mixed | - | 67.8 (8.0-90.0) | - | - |
| 16,973  | ≥18 years | B.1.617.2 (Delta) | - | 65.2 (33.1-83.0) | - | - |
| 16,973  | ≥18 years | B.1.617.1 (Kappa) | - | 90.1 (30.4-99.8) | - | - |
| **Non-replicating vector** |
| Gam-COVID-Vac | Russian Gamaleya NRCEM | Russia15 | 18,695  | ≥18 years | RCT/Efficacy | Prototype | 14 days after dose 2 | - | 91.1 (83.8-95.1) | - | 100.0 (94.4-100.0) |
| Ad26.COV2.S | Janssen | United States, Brazil, South Africa16 | 39,058  | ≥18 years | RCT/Efficacy | Prototype, P.1, B.1.351 | 14 days after dose 1 | - | 66.9 (59.1-73.4) | - | 76.7 (54.6-89.1) |
| 29,111  | 18-59 years | - | 65.8 (56.2-73.1) | - | - |
| 14,672  | ≥ 60 years | - | 74.5 (57.9-84.3) | - | - |
| South Africa | 4,969 | ≥18 years | RCT/Efficacy | B.1.351 | 14 days after dose 1 | - | 52.0 (30.3-67.4) | - | 73.1 (40.0-89.4) |
|  |  | United States, Brazil, South Africa16 | 39,058  | ≥18 years | RCT/Efficacy | Prototype, P.1, B.1.351 | 28 days after dose 1 | - | 66.1 (55.0-74.8) | - | 85.4 (54.2-96.9) |
|  |  | 29,111  | 18-59 years | - | 69.3 (57.4-77.7) | - | - |
|  |  | 14,672  | ≥ 60 years | - | 67.9 (38.2-82.8) | - | - |
|  |  | South Africa16 | 4,969 | ≥18 years | RCT/Efficacy | B.1.351 | 28 days after dose 1 | - | 64.0 (41.2-78.7) | - | 81.7 (46.2-95.4) |
| ChAdOx1-S | AstraZeneca | United Kingdom, Brazil, South Africa17 | 12,604  | ≥18 years | RCT/Efficacy | Prototype | 21 days after dose 1 | 46.3 (31.8-57.8) | 58.3 (44.0-68.9) | 100 | 100 |
| 11,636  | ≥18 years | 14 days after dose 2 | 55.7 (41.1-66.7) | 70.4 (54.8-80.6) | 100 | 100 |
| South Africa18 | 1,464  | ≥18 years | RCT/Efficacy | B.1.351 | 14 days after dose 2 | - | 10.4 (-76.8-54.8) | - | - |
| United Kingdom19 | 8,534  | ≥18 years | RCT/Efficacy | B.1.1.7 | 14 days after dose 2 | 61.7 (36.7-76.9) | 70.4 (43.6-84.5) | 100 | - |
| **Protein subunit** |
| NVX-CoV2373 | Novavax | United Kingdom20 | 14,039  | ≥18 years | RCT/Efficacy | Non-B.1.1.7 | 7 days after dose 2 | - | 96.4 (73.6-99.5) | 100 | 100 |
| 14,039  | ≥18 years | B.1.1.7 | - | 86.3 (71.3-93.5) | 100 | 100 |
| South Africa21 | 2,536  | ≥18 years | B.1.351 | - | 60.1 (19.9-80.1) | - | - |

## Table S4. Summary of vaccine effectiveness from included studies

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **Developer** | **Study location** | **Population size** | **Age range** | **Design/Measure of effect** | **Circulation of VOCs** | **Period** | **Against infection** | **Against symptomatic case** | **Against hospitalization** | **Against severe outcome** |
| **mRNA** |
| BNT162b2 | BioNTech/Pfizer | United Kingdom22,23 | 11,621  | ≥16 years | test-negative/Effectiveness | B.1.1.7 | 21 days after dose 1 | - | 47.5 (41.6-52.8) | 83 (62-93) | - |
| 11,621  | ≥16 years | B.1.1.7 | 14 days after dose 2 | - | 93.7 (91.6-95.3) | 95 (78-99) | - |
| 1,054  | >16 years | B.1.1.7 | 21 days after dose 1 | - | 35.6 (22.7-46.4) | 94 (46-99) | - |
| 1,054  | >16 years | B.1.1.7 | 14 days after dose 2 | - | 88.0 (85.3-90.1) | 96 (86-99) | - |
|  | 18-64 years | B.1.617.2  | 14 days after dose 2 | 82 (79-85) | 86 (83-88) | - | - |
| Qatar24 | 37,934  | ≥16 years |  | After dose 1 | 29.5 (22.9-35.5) | - | - | 54.1 (26.1-71.9) |
| 32,808  | ≥16 years |  | 14 days after dose 2 | 89.5 (85.9-92.3) | - | - | 100.0 (81.7-100.0) |
| 43,012  | ≥16 years | B.1.351 | After dose 1 | 16.9 (10.4-23.0) | - | - | 0.0 (0.0-19.0) |
| 39,150  | ≥16 years | B.1.351 | 14 days after dose 2 | 75.0 (70.5-78.9) | - | - | 100.0 (73.7-100.0) |
|  | ≥16 years | B.1.617.2 | After dose 1 | 65.5 (40.9-79.9) | 76.3 (46.7-90.7) | - | 100 (NE) |
|  | ≥16 years | B.1.617.2 | 14 days after dose 2 | 59.6 (50.7-66.9) | 56.1 (41.4-67.2) | - | 97.3 (84.4-95.5) |
| Scotland25 | 199,375  | ≥16 years | test-negative/Effectiveness | B.1.617.2  | 0-27 days after dose 1 | 12 | 18 | - | - |
| 199,375  | ≥16 years | 28 days after dose 1 | 30 | 33 | - | - |
| 199,375  | ≥16 years | 0-13 days after dose 2 | 66 | 84 | - | - |
| 199,375  | ≥16 years | 14 days after dose 2 | 79 | 83 | - | - |
| 199,375  | ≥16 years | B.1.1.7 | 0-27 days after dose 1 | 31 | 28 | - | - |
| 199,375  | ≥16 years | 28 days after dose 1 | 38 | 27 | - | - |
| 199,375  | ≥16 years | 0-13 days after dose 2 | 73 | 78 | - | - |
| 199,375  | ≥16 years | 14 days after dose 2 | 92 | 92 | - | - |
| Canada23 |  | ≥16 years | test-negative/Effectiveness | B.1.1.7 | 14 days after dose 1 | - | 66 (64-68) | 80 (78-82) | - |
|  | ≥16 years | 21 days after dose 1 | - | 69 (67-71) | 85 (83-86) | - |
|  | ≥16 years | 7 days after dose 2 | - | 89 (86-91) | 95 (9-97) | - |
|  | ≥16 years | 14 days after dose 2 | - | 89 (87-91) | 96 (93-98) | - |
|  | ≥16 years | B.1.351/P.1 | 14 days after dose 1 | - | 60 (52-67) | 77 (69-83) | - |
|  | ≥16 years | 21 days after dose 1 | - | 65 (56-71) | 83 (75-88) | - |
|  | ≥16 years | 7 days after dose 2 | - | 84 (69-92) | 95 (81-99) | - |
|  | ≥16 years | 14 days after dose 2 | - | 85 (70-93) | 98 (82-100) | - |
|  | ≥16 years | B.1.617.2 | 14 days after dose 1 | - | 56 (45-64) | 78 (65-86) | - |
|  | ≥16 years | 21 days after dose 1 | - | 61 (51-70) | 78 (64-87) | - |
|  | ≥16 years | 7 days after dose 2 | - | 87 (64-95) | - | - |
|  | ≥16 years | 14 days after dose 2 | - | 85 (59-94) | - | - |
| mRNA-1273 | Moderna | Qatar26 |  | ≥18 years | test-negative/Effectiveness | B.1.1.7 | 14 days after dose 1 | 88.1 (83.7-91.5) | - | - | - |
|  | ≥18 years | 14 days after dose 2 | 100.0 (91.8-100) | - | - | - |
|  | ≥18 years | B.1.351 | 14 days after dose 1 | 61.3 (56.5-65.5) | - | - | - |
|  | ≥18 years | 14 days after dose 2 | 96.4 (91.9-98.7) | - | - | - |
| Canada27 |  | ≥18 years | B.1.1.7 | 14 days after dose 1 | - | - | - | - |
|  | ≥18 years | 21 days after dose 1 | - | - | - | - |
|  | ≥18 years | 7 days after dose 2 | - | - | - | - |
|  | ≥18 years | 14 days after dose 2 | - | - | - | - |
|  | ≥18 years | B.1.351/P.1 | 14 days after dose 1 | - | - | - | - |
|  | ≥18 years | 21 days after dose 1 | - | - | - | - |
|  | ≥18 years | B.1.617.2  | 14 days after dose 1 | - | - | - | - |
|  | ≥18 years | 21 days after dose 1 | - | - | - | - |
| **Inactivated** |  |  |
| CoronaVac | SinoVac | Brazil28 | 2,797  | ≥18 years | test-negative/Effectiveness | P.1 | 14 days after dose 1 | 35.1 (-6.6-60.5) | 49.6 (11.3-71.4) | - | - |
| 1,665  | ≥18 years | 14 days after dose 2 | 37.9 (-46.4-73.6) | 36.8 (-54.9-74.2) | - | - |
|  |  | Brazil29 |  | ≥70 years | test-negative/Effectiveness | P.1 | 14 days after dose 2 | - | 41.6 (26.9-53.3) | 59.0 (44.2-69.8) | 71.4 (53.7-82.3) (death) |
|  |  |  |  | 70-74 years | - | 61.8 (34.8-77.7) | 80.1 (55.7-91.0) | 86.0 (50.4-96.1) (death) |
|  |  |  |  | 75-79 years | - | 48.9 (23.3-66.0) | 69.5 (42.4-83.8) | 87.1 (60.2-95.8) (death) |
|  |  |  |  | ≥80 years | - | 28.0 (0.60-47.9) | 43.4 (15.4-62.0) | 49.9 (8.1-72.7) (death) |
| **Non-replicating vector** |  |  |
| ChAdOx1-S | AstraZeneca | United Kingdom22,23 | 11,621  | ≥18 years | test-negative/Effectiveness | B.1.1.7 | 21 days after dose 1 | - | 48.7 (45.2-51.9) | 76 (61-85) | - |
| 11,621  | ≥18 years | 14 days after dose 2 | - | 74.5 (68.4-79.4) | 86 (53-96) | - |
| 1,054  | ≥18 years | B.1.617.2  | 21 days after dose 1 | - | 30.0 (24.3-35.3) | 71 (51-83) | - |
| 1,054  | ≥18 years | 14 days after dose 2 | - | 67.0 (61.3-71.8) | 92 (75-97) | - |
| Scotland25 | 199,375  | ≥18 years | test-negative/Effectiveness | B.1.617.2  | 0-27 days after dose 1 | 7 | 23 | - | - |
| 199,375  | ≥18 years | 28 days after dose 1 | 18 | 33 | - | - |
| 199,375  | ≥18 years | 0-13 days after dose 2 | 25 | 37 | - | - |
| 199,375  | ≥18 years | 14 days after dose 2 | 60 | 61 | - | - |
| 199,375  | ≥18 years | B.1.1.7 | 0-27 days after dose 1 | 9 | 17 | - | - |
| 199,375  | ≥18 years | 28 days after dose 1 | 37 | 39 | - | - |
| 199,375  | ≥18 years | 0-13 days after dose 2 | 64 | 65 | - | - |
| 199,375  | ≥18 years | 14 days after dose 2 | 73 | 81 | - | - |
| Brazil30 |  | ≥60 years | test-negative/Effectiveness | P.1 | 28 days after dose 1 | - | 33.4 (26.4-39.7) | 55.1 (46.6-62.2) | ICU admission: 50.9 (-41.8-83)Invasive mechanical ventilation: 70.5 (54.9-80.8)Death: 61.8 (48.9-71.4) |
|  | ≥60 years | 14 days after dose 2 | - | 77.9 (69.2-84.2) | 87.6 (78.2-92.9) | ICU admission: 89.9 (70.9-96.5)Invasive mechanical ventilation: 96.5 (81.7-99.3)Death: 93.6 (81.9-97.7) |
| Canada27 |  | ≥18 years | test-negative/Effectiveness | B.1.1.7 | 14 days after dose 1 | - | 64 (60-68) | 85 (81-88) | - |
|  | ≥18 years |  | 21 days after dose 1 | - | 72 (68-76) | 90 (86-93) | - |
|  | ≥18 years |  | 7 days after dose 2 | - | 79 (-57-97) | 67 (-155-96) | - |
|  | ≥18 years |  | 14 days after dose 2 | - | 75 (-98-97) | - | - |
|  | ≥18 years |  | B.1.351/P.1 | 7 days after dose 2 | - | 48 (28-63) | 83 (66-92) | - |
|  | ≥18 years |  | 14 days after dose 2 | - | 50 (27-66) | 82 (91-92) | - |
|  | ≥18 years |  | B.1.617.2  | 7 days after dose 2 | - | 67 (44-80) | 88 (60-96) | - |
|  | ≥18 years |  | 14 days after dose 2 | - | 70 (46-83) | 87 (56-96) | - |

## Table S5. Fold change of neutralization antibody level used in this study1

|  |  |  |  |
| --- | --- | --- | --- |
| Vaccine | Variants (Pango lineage) | Fold change of neutralization titer (95%CI) | Type of neutralization assay |
| BNT162b2 | Alpha (B.1.1.7) | 1.13 (1.02-1.25) | Live virus neutralization assay |
| BNT162b2 | Beta (B.1.351) | 4.63 (4.20-5.10) | Live virus neutralization assay |
| BNT162b2 | Gamma (P.1) | 1.98 (1.65-2.36) | Live virus neutralization assay |
| BNT162b2 | Delta (B.1.617.2) | 0.99 (0.81-1.20) | Live virus neutralization assay |
| mRNA-1273 | Alpha (B.1.1.7) | 0.87 (0.61-1.25) | Live virus neutralization assay |
| mRNA-1273 | Beta (B.1.351) | 5.33 (4.07-6.98) | Live virus neutralization assay |
| mRNA-1273 | Delta (B.1.617.2) | 3.37 (2.21-5.15) | Live virus neutralization assay |
| Ad26.COV2.S | Alpha (B.1.1.7) | 0.61 (0.41-0.93) | Lentivirus-vector pseudovirus neutralization assay |
| Ad26.COV2.S | Beta (B.1.351) | 3.05 (2.16-4.31) | Lentivirus-vector pseudovirus neutralization assay |
| Ad26.COV2.S | Gamma (P.1) | 1.30 (0.74-2.26) | Lentivirus-vector pseudovirus neutralization assay |
| Ad26.COV2.S | Delta (B.1.617.2) | 2.54 (1.84-3.49) | Lentivirus-vector pseudovirus neutralization assay |
| ChAdOx1 nCoV-19 | Alpha (B.1.1.7) | 0.74 (0.54-1.02) | Live virus neutralization assay |
| ChAdOx1 nCoV-19 | Beta (B.1.351) | 3.55 (2.50-5.04) | Live virus neutralization assay |
| ChAdOx1 nCoV-19 | Gamma (P.1) | 1.38 (0.96-1.99) | Live virus neutralization assay |
| ChAdOx1 nCoV-19 | Delta (B.1.617.2) | 3.49 (2.44-4.97) | Live virus neutralization assay |
| Gam-COVID-Vac | Alpha (B.1.1.7) | 0.60 (0.34-1.06) | VSV-vector pseudovirus neutralization assay |
| Gam-COVID-Vac | Beta (B.1.351) | 4.78 (2.04-11.22) | VSV-vector pseudovirus neutralization assay |
| NVX-CoV2373 | Alpha (B.1.1.7) | 2.08 (1.18-3.66) | Lentivirus-vector pseudovirus neutralization assay |
| NVX-CoV2373 | Beta (B.1.351) | 18.50 (11.47-29.86) | Lentivirus-vector pseudovirus neutralization assay |

## Table S6. Model parameters used in prediction of efficacy

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Model structure | LL | AIC | Slope (***k***) | Pooled SD ()a |
| Fitting protection from symptomatic vs severe COVID-19 |
| Different 𝒏𝟓𝟎 a | -66.08  | 138.16 | 2.94 (2.14-4.04) | 0.44 |
| Fitting protection from symptomatic COVID-19 vs SARS-CoV-2 infection |
| Different 𝒏𝟓𝟎 | -61.10 | 128.20 | 2.88 (2.19-3.78) | 0.44 |
| Same 𝒏𝟓𝟎 | -70.09 | 144.18 | 2.31 (1.80-2.96) | 0.44 |

a indicates the parameter was extracted from *Khoury et al.2*

## Table S7. Comparison of predicted efficacy and efficacy/effectiveness in published data.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vaccine | Variants(Pango lineage) | Efficacy in published data (%) | Effectiveness in published data (%) | Predicted efficacy (%) |
| Against SARS-CoV-2 infection |
| ChAdOx1 nCoV-19 | Alpha (B.1.1.7) | United Kingdom: 61.7 (36.7-76.9) | Scotland: 73 | 62.7 (40.7-78.7) |
| ChAdOx1 nCoV-19 | Delta (B.1.617.2) | - | Scotland: 60United Kingdom: 67 (62-71) | 27.5 (12.4-46.0) |
| mRNA-1273 | Alpha (B.1.1.7) | - | Qatar: 100.0 (91.8-100) | 90.9 (87.2-93.7) |
| mRNA-1273 | Beta (B.1.351) | - | Qatar: 96.4 (91.9-98.7) | 61.6 (55.3-67.5) |
| mRNA-1273 | Delta (B.1.617.2) |  | Qatar: 86.1 (78.0-91.3) | 71.4 (62.3-79.1) |
| Against COVID-19 symptomatic cases |
| Ad26.COV2.S | Beta (B.1.351) | South Africa: 52.0 (30.3-67.4) |  | 40.4 (25.5-56.3) |
| BNT162b2 | Alpha (B.1.1.7) | - | Canada: 89 (87-91)Scotland: 92United Kingdom: 93.7 (91.6-95.3) | 94.3 (87.9-97.5) |
| BNT162b2 | Delta (B.1.617.2) | - | Canada: 85 (59-94)Scotland: 83United Kingdom: 88.0 (85.3-90.1)United Kingdom: 86 (83-88) | 95.1 (88.4-98.1) |
|  |  |  | Qatar: 56.1 (41.4-67.2) |  |
| mRNA-1273 | Alpha (B.1.1.7) | - | Canada: 91 (84-95) | 94.9 (86.8-98.2) |
| mRNA-1273 | Delta (B.1.617.2) | - | Canada: 72 (57-82)Qatar: 85.8 (70.6-93.9) | 80.8 (60.7-92.3) |
| ChAdOx1 nCoV-19 | Alpha (B.1.1.7) | United Kingdom: 70.4 (43.6-84.5) | Canada: 75 (-98-97)Scotland: 81United Kingdom: 74.5 (68.4-79.4) | 76.3 (54.4-89.0) |
| ChAdOx1 nCoV-19 | Beta (B.1.351) | South Africa: 10.4 (-76.8-54.8) | - | 40.7 (19.5-62.3) |
| ChAdOx1 nCoV-19 | Delta (B.1.617.2) | - | Canada: 70 (46-83)Scotland: 61United Kingdom: 67.0 (61.3-71.8)United Kingdom: 70 (66-74) | 41.1 (19.8-62.8) |
| ChAdOx1 nCoV-19 | Gamma (P.1) | - | Brazil: 77.9 (69.2-84.2) | 63.3 (38.3-81.2) |
| NVX-CoV2373 | Alpha (B.1.1.7) | United Kingdom: 86.3 (71.3-93.5) |  | 92.0 (43.7-99.4) |
| NVX-CoV2373 | Beta (B.1.351) | South Africa: 60.1 (19.9-80.1) |  | 54.4 (8.1-91.2) |
| Against severe COVID-19 |
| Ad26.COV2.S | Beta (B.1.351) | South Africa: 73.1 (40.0-89.4) | - | 52.5 (22.4-78.5) |
| BNT162b2 | Alpha (B.1.1.7) | - | Qatar: 100.0 (81.7-100.0) | 72.6 (0.1-99.5) |
| BNT162b2 | Beta (B.1.351) | - | Qatar: 100.0 (73.7-100.0) | 40.3 (0.0-97.2) |
| BNT162b2 | Delta (B.1.617.2) | - | Qatar: 97.3 (84.4-95.5) | 75.3 (0.1-99.6) |
| ChAdOx1 nCoV-19 | Gamma (P.1) | - | Brazil: 96.5 (81.7-99.3) | 99.8 (99.8-99.9) |
| NVX-CoV2373 | Alpha (B.1.1.7) | United Kingdom: 100  | - | 99.7 (99.5-99.9) |

# Supplementary figures

## Figure S1. Predicted efficacy against infection for the variants of concern

Predicted efficacy against SARS-CoV-2 infection among reference lineages (blue bar), Alpha variant (orange bar), Beta variant (red bar), Gamma variant (green bar), and Delta variant (purple bar) were determined in **A)** mRNA-1273 and **B)** ChAdOx1 nCoV-19. The error bar represents the uncertainty interval.



## Figure S2. Predicted age-specific efficacy against symptomatic illness for the Delta variant for BNT162b2

The error bar represents the uncertainty interval.



## Figure S3. Predicted efficacy against symptomatic illness for the variants of concern

Predicted efficacy against symptomatic illness among reference lineages (blue bar), Alpha variant (orange bar), Beta variant (red bar), Gamma variant (green bar), and Delta variant (purple bar) were determined in **A)** BNT162b2, **B)** mRNA-1273, **C)** Ad26.COV2.S, **D)** ChAdOx1 nCoV-19, **E)** Gam-COVID-Vac and **F)** NVX-CoV2373. The error bar represents the uncertainty interval.



## Figure S4. Predicted age-specific efficacy against the symptomatic illness for the variants of concern

Predicted age-specific efficacy against symptomatic illness among reference lineages (blue bar), Alpha variant (orange bar), Beta variant (red bar), Gamma variant (green bar) and Delta variant (purple bar) were determined in **A)** BNT162b2 and **B)** mRNA-1273. The error bar represents the uncertainty interval.



## Figure S5. Predicted efficacy against the severe illness for the variants of concern

Predicted efficacy against severe illness among reference lineages (blue bar), Alpha variant (orange bar), Beta variant (red bar), Gamma variant (green bar) and Delta variant (purple bar) were determined in **A)** BNT162b2, **B)** mRNA-1273, **C)** Ad26.COV2.S and **D)** Gam-COVID-Vac. The error bar represents the uncertainty interval.



## Figure S6. Comparison of predicted efficacy and observed efficacy or effectiveness across different endpoints for the variants of concern

Predicted efficacy was compared with observed efficacy and effectiveness against **A)** SARS-CoV-2 infection, **B)** symptomatic cases and **C)** severe COVID-19. The colors represent different SARS-CoV-2 variants, including Alpha (orange), Beta (red), Gamma (green) and Delta variant (purple bar). The error bar represents the uncertainty interval.



# Reference

1. Chen X, Chen Z, Azman AS, et al. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination. 2021: 2021.05.03.21256506.

2. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine* 2021.

3. Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding COVID-19. *Immunity* 2021; **54**(1): 14-8.

4. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. *Nature reviews Immunology* 2020; **20**(10): 581-2.

5. Frenck RW, Jr., Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *The New England journal of medicine* 2021.

6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.

7. Thomas SJ, Moreira ED, Kitchin N, et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. 2021: 2021.07.28.21261159.

8. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *The New England journal of medicine* 2021; **384**(5): 403-16.

9. Albuquerque; RPAPBCSN. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. *SSRN* 2021.

10. Clemens S, Folegatti P, Emary K, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial; 2021.

11. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet* 2021; **398**(10296): 213-22.

12. WHO. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. 2021. <https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf?sfvrsn=2488098d_5> (accessed April 29

13. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *Jama* 2021.

14. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. 2021: 2021.06.30.21259439.

15. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet (London, England)* 2021; **397**(10275): 671-81.

16. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**(23): 2187-201.

17. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021; **397**(10269): 99-111.

18. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* 2021; **384**(20): 1885-98.

19. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet* 2021.

20. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *N Engl J Med* 2021.

21. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *The New England journal of medicine* 2021; **384**(20): 1899-909.

22. Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *medRxiv* 2021: 2021.05.22.21257658.

23. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *The New England journal of medicine* 2021: NEJMoa2108891.

24. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* 2021.

25. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet (London, England)* 2021; **397**(10293): 2461-2.

26. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nature medicine* 2021.

27. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. 2021: 2021.06.28.21259420.

28. Hitchings MDT, Ranzani OT, Scaramuzzini Torres MS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *medRxiv* 2021: 2021.04.07.21255081.

29. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study. 2021: 2021.05.19.21257472.

30. Hitchings MDT, Ranzani OT, Dorion M, et al. Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil. 2021: 2021.07.19.21260802.